Redefining Treatment Success in the Modern Psoriasis Era

Psoriasis management has undergone a profound evolution over the past 2 decades. What was once considered “good control” is now increasingly viewed as inadequate—by clinicians and patients. In a Dermatology Times Clinical Case Collective forum, Raj Chovatiya, MD, PhD, MSCI, clinical associate professor of dermatology at Northwestern University Feinberg School of Medicine; George Michael Lewitt, MD, assistant professor of dermatology at Icahn School of Medicine at Mount Sinai and a member of the National Psoriasis Foundation (NPF) medical board; and Christopher Arico, MS, PA-C, physician assistant specializing in dermatology, discussed how treat-to-target strategies in psoriasis have evolved, why higher expectations are now achievable, and how clinicians can better integrate objective disease measures with patient-reported burden.

Chovatiya opened the discussion by grounding the conversation in epidemiology, noting that psoriasis affects more than 7.5 million adults in the United States. However, prevalence alone fails to capture the huge shift in treatment expectations. Reflecting on earlier eras of systemic therapy, Chovatiya remarked that benchmarks such as a 50% reduction in the Psoriasis Area and Severity Index (PASI 50) or PASI 75 once allowed clinicians to “go to bed at night and feel good about ourselves that we had done well by our patients.” As therapeutic options have advanced, he emphasized, that bar has steadily risen.

Early Intervention

Lewitt highlighted the importance of early and decisive intervention, emphasizing that psoriasis should be treated as a systemic inflammatory disease rather than a skin-only condition. In his clinical practice, he said, he often reframes the discussion directly for patients: “You have a systemic condition; you deserve a systemic therapy.”

This shift in framing supports more timely use of advanced systemic agents, particularly biologics, with the goal of altering the disease trajectory rather than merely suppressing visible plaques. Lewitt explained that intervening early may allow clinicians to “quickly change the phenotype and withhold control early,” suggesting a potential to modify long-term disease expression.

Rising Expectations in the Biologic Era

Arico reflected on how dramatically expectations have changed since he entered dermatology practice in 2007. At that time, he noted, therapeutic options were limited, and consistent PASI 75 responses were far from guaranteed. Comparing therapeutic innovation to consumer technology, Arico stated, “It’s almost like the advent of smartphones.... I feel like we’re on version 4 or version 5 at this point.”

Lewitt agreed, noting that patient expectations have evolved in parallel with drug development. Patients are no longer satisfied with partial improvement, he said, adding that they no longer want “an iPhone 8”—they want the latest model.

Limitations of PASI

Although PASI remains a cornerstone outcome measure in clinical trials, the panel acknowledged its limited utility in routine practice. As Chovatiya stated, “PASI 75 is a very clinician-centered term.” Patients, he noted, do not experience their disease in percentages or composite indices.

To address this gap, contemporary guidelines, particularly those from the NPF, have increasingly emphasized body surface area (BSA) as a more intuitive metric. Lewitt outlined current treat-to-target recommendations: Within 3 months of initiating therapy, the ideal target is less than 1% of BSA involvement, with less than 3% considered an acceptable response or at least a 75% improvement from baseline.

Defining On-Treatment Remission

A key forward-looking concept discussed during the forum was on-treatment remission. This framework acknowledges psoriasis as a chronic condition requiring ongoing therapy while recognizing that sustained complete clearance is now achievable for many patients.

Lewitt described on-treatment remission as achieving “zero BSA or an IGA of zero...for at least 6 months.” He noted that this definition was developed through a Delphi process involving dermatologists, rheumatologists, and patients. While the definition focuses on cutaneous disease, it reflects a broader shift toward sustained disease control rather than episodic improvement.

High-Impact Sites and Disease Burden

Despite the usefulness of BSA-based targets, the panel emphasized that numerical thresholds alone do not capture the full burden of disease. Residual involvement of high-impact sites—such as the scalp, face, genitals, hands, feet, or nails—can significantly impair quality of life even when overall BSA is low.

Lewitt summarized this challenge succinctly, explaining that “it all depends where that 1% to 3% lies on that person.” He stressed the importance of direct, sensitive questioning, particularly about areas patients may be hesitant to discuss without prompting.

Patient-Reported Outcomes

The speakers also addressed the limitations of broad quality-of-life questions. Patients frequently respond with “I’m fine,” which may obscure ongoing functional or emotional distress. Arico described using targeted, situational questions—about intimacy, clothing choices, or participation in physical activity—to uncover unmet needs.

Validated tools such as the Dermatology Life Quality Index were highlighted as efficient screening instruments. Chovatiya offered a practical alternative, suggesting clinicians ask whether there is anything the disease prevents the patient from doing that they wish they could do, which often reveals concerns that would otherwise go unspoken.

Communicating Goals

When discussing treat-to-target goals with patients, the panel favored a collaborative and optimistic approach. Lewitt acknowledged that direct-to-consumer advertising has increased awareness of what is possible, while Arico emphasized the need to translate immunologic concepts into accessible language.

The consensus was clear: Modern psoriasis care is no longer about accepting partial improvement. With an expanding therapeutic armamentarium, clinicians now have the tools to pursue sustained clearance and meaningful quality-of-life gains.